Clinical and angiographic outcomes following elective implantation of the carbostent in patients at high risk of restenosis and target vessel failure

The Carbostent is a new balloon‐expandable, stainless steel, tubular stent with innovative multicellular design and unique turbostratic carbon coating. The aim of this study was to assess clinical and angiographic outcomes after Carbostent implantation in 112 patients poorly suitable for an effective treatment with stenting because of the high risk of thrombosis, late restenosis, and clinical target vessel failure. The inclusion criteria were age > 75 years, diabetes mellitus, a lesion length > 10 mm, a reference vessel diameter < 3.0 mm, an ostial location of the target lesion, and chronic total occlusion. Overall, a total of 175 stents ranging from 9 to 25 mm in length were placed in 147 lesions. There were no stenting attempt failures. The acute gain after stent implantation was 2.46 ± 0.51 mm, and the residual stenosis 0 ± 4%. No stent thrombosis occurred, nor myocardial infarction. The 6‐month event‐free survival rate was 74% ± 5%. The 6‐month angiographic follow‐up showed a late loss of 0.81 ± 0.88 mm and a binary (≥ 50%) restenosis rate of 25%. The results of this study suggest that the Carbostent may be highly effective in patients at high risk of restenosis and target vessel failure. Cathet Cardiovasc Intervent 2001;54:420–426. © 2001 Wiley‐Liss, Inc.